Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)
Sponsor: IBSA Institut Biochimique SA
Summary
This is a multi-center, prospective, parallel-group, open-label, randomized clinical study in one hundred and twenty-six (126) neonates and infants diagnosed with CH. Subjects will be randomized in a 2:1 ratio to Treatment (Tirosint®-SOL) or Control (conventional therapy with levothyroxine sodium crushed tablets).
Official title: A Randomized Comparative Study Between Liquid (Tirosint®-SOL) and Tablet Formulations of Levothyroxine in Neonates and Infants With Congenital Hypothyroidism
Key Details
Gender
All
Age Range
1 Day - 9 Months
Study Type
INTERVENTIONAL
Enrollment
34
Start Date
2022-01-21
Completion Date
2025-03-27
Last Updated
2026-05-29
Healthy Volunteers
No
Conditions
Interventions
Tirosint®-SOL
Dosage will be according to the USPI and Standard of Care.
Levothyroxine Sodium
Tablets will be crushed and dissolved in solution. Dosage will be according to the USPI and Standard of Care.
Locations (10)
Children's Hospital of Los Angeles
Los Angeles, California, United States
CHOC Children's Hospital
Orange, California, United States
University of California San Francisco
San Francisco, California, United States
Yale University
New Haven, Connecticut, United States
Children's Hospital of Atlanta
Atlanta, Georgia, United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Children's Mercy Hospital and Clinics
Kansas City, Missouri, United States
Children's Hospital Medical Center
Cincinnati, Ohio, United States
Cook Children's Health Care Systems
Fort Worth, Texas, United States